Reviewing the safety of erlotinib in non-small cell lung cancer

Bibliography

• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S-40S
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59
   PubMed Web of Science ®Google Scholar
• Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 2009;14:1116-30
   PubMed Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48
   PubMed Web of Science ®Google Scholar
• Akita RW, Sliwkowski MX. Preclinical studies with Erlotinib (Tarceva). Semin Oncol 2003;30(3 Suppl 7):15-24
   PubMed Web of Science ®Google Scholar
• Friess T, Scheuer W, Hasmann M. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. Anticancer Res 2006;26(5A):3505-12
   PubMed Web of Science ®Google Scholar
• Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11:5300-9
   PubMed Web of Science ®Google Scholar
• Higgins B, Kolinsky K, Smith M, Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small-cell lung cancer tumor xenograft models. Anticancer Drugs 2004;15:503-12
   PubMed Web of Science ®Google Scholar
• Ling J, Johnson KA, Miao Z, Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006;34:420-6
   PubMed Web of Science ®Google Scholar
• Tarceva® summary of product characteristics. Roche Registration Ltd. 2010. Available from: http://www.ema.europa.eu/humandocs/Humans/EPAR/tarceva/tarceva.htm. [Last accessed 08 06 10]
   Google Scholar
• Hamilton M, Wolf JL, Rusk J, Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-71
   PubMed Web of Science ®Google Scholar
• Lu JF, Eppler SM, Wolf J, Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006;80:136-45
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47
   PubMed Web of Science ®Google Scholar
• Shepherd F, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Bezjak A, Tu D, Seymour L, Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-7
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9
   PubMed Web of Science ®Google Scholar
• Vamvakas L, Agelaki S, Kentepozidis NK, Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial [abstract]. J Clin Oncol 2010;28(Suppl 15 Pt I):7519
   Google Scholar
• Reck M, Van Zandwijk N, Gridelli C, Erlotinib in advanced non-small-cell lung cancer (NSCLC): efficacy and safety findings of the global phase IV TRUST Study. J Thorac Oncol 2010;10:1616-22
   Google Scholar
• Mok T, Park K, Au J S-K, Efficacy and safety of erlotinib in >1200 East/South-East Asian patients with advanced non-small-cell lung cancer. J Thorac Oncol 2010;5:1609-15
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn KR, Chang S, Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8:67-78
   PubMed Web of Science ®Google Scholar
• Mita A, Farouzesh B, Hidalgo M. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (HER1/EGFR-TK) inhibitor erlotinib (OSI-774; TarcevaTM) in combination with docetaxel [abstract]. Eur J Cancer 2002;38(Suppl 7):S53, 168a
   Google Scholar
• Patnaik A, Wood D, Tolcher AW, Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006;12:7406-13
   PubMed Web of Science ®Google Scholar
• George CM, Desai AA, Janisch L, Phase I trial of erlotinib HCL (E; OSI-774) in combination with gemcitabine (G) and cisplatin (C) [abstract]. Proc Am Soc Clin Oncol 2003;22:229, 916a
   PubMedGoogle Scholar
• Twelves C, Trigo JM, Jones R, Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008;44:419-26
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Verslype C, Beale P, A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 2008;19:332-9
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Cassidy J, Sastre J, Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clin Cancer Res 2007;13(Suppl 2 Pt 1):523-31
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-52
   PubMed Web of Science ®Google Scholar
• Herbst R, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Tran HT, Zinner RG, Blumenschein GR Jr, Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 2010: published online 22 January 2010, doi: 10.1007/s10637-009-9380-z
   Google Scholar
• Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 2008;22:1470-9
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Yu CJ, Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7
   PubMed Web of Science ®Google Scholar
• Miller VA, O'Connor P, Soh C, A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2009;27(Suppl 18 Pt II):LBA8002a
   Google Scholar
• Hainsworth J, Herbst R. A Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BETA) [late breaking abstract]. J Thorac Oncol 2008;3(Suppl 4):S302
   Google Scholar
• Schiller JH, Akerley WL, Brugger W, Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;28(Suppl 18 Pt II):LBA7502
   Google Scholar
• Huang Y-S, An S-J, Chen Z-H, Three cases of severe hepatic impairment caused by erlotinib. Br J Clin Pharmacol 2009;68:464-67
   PubMed Web of Science ®Google Scholar
• Besse B, Smit EF, Felip E, First-line erlotinib in stage IIIB/IV non-small-cell lung cancer (NSCLC) with dose escalation to toxicity in current and former smokers (C/FS): a phase II study [abstract]. Ann Oncol 2008;19(Suppl 8):viii101, 267Pa
   Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-l, Chen G, Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL) [abstract]. J Clin Oncol 2010;28(Suppl 15 Pt I):556s, 7575a
   PubMedGoogle Scholar
• Reck M, Gutzmer R. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor (EGFR) inhibition. Onkologie 2010;33:470-9
   PubMed Web of Science ®Google Scholar
• Iressa® Summary of Product Characteristics. AstraZeneca AB, 2009. Available from: http://www.ema.europa.eu/humandocs/Humans/EPAR/iressa/iressa.htm [Last accessed 28 July 2010]
   Google Scholar
• Zhu CQ, da Cunha Santos G, Ding K, ; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75
   PubMed Web of Science ®Google Scholar
• Clark GM, Perez-Soler R, Siu L, Rash severity is predictive of increased survival with erlotinib hydrochloride [abstract]. Proc Am Soc Clin Oncol 2003;22:196, 786a
   Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47
   PubMed Web of Science ®Google Scholar
• Giaccone G, Gallegos Ruiz M, Le Chevalier T, Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-55
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Lindeman NI, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-6
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Kim ES, Eaby B, Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar